IL17A and psoriasis: The final analysis included 17 controls and 84 patients with psoriasis receiving monotherapy with methotrexate (17 [20%] patients), TNF inhibitors (27 [32%]), IL-17 inhibitors (15 [18%]), or IL-23 inhibitors (25 [30%]), all without concurrent glucocorticoids (figure 1).